Member Info for TheRiflemans

Absolute nightmare and could not have happened at a worse time. If it were me I'd be suing them. Could prove costly in terms of lost business, refunds and in compensation.

Sub 20p incoming

Coldspy there is a Q4 production report due around the 11th Jan. I won't be holding any shares into that. I might even look at shorting it.

Whose to say that there aren't other electrolyser companies tasked to provide a FEED then the client decides what best meets their needs. For all we know Sunfire could have received the same FEED consultancy. The client then decides.

Retracing almost daily. Could 75p or 70p be on the cards..

You do realise that the contract is only for the Front-End Engineering Design.

So a consultancy fee only at this point in time

There should be a trading update in early January, which with Russia taking out electricity infrastructure, again recently, I don't think will read well. So much for peace in a day.

It's not moving the share price though and there must be a r4asonable chance this finishes the day in the ..teens

Mr Market gave both sides a thumbs down. It's where it goes if it breaches 20p

Wise to be dumping as in the UK they normally all end up lower than they were prior. Kosmos not interested and theCEO departing also. What's hiding in the closet?

Was obvious it would retrace when it double topped at 90p. Low to mid 70's might be time to book in again. Shorts in control again.

Perhaps double topped so the top slice might not have been a bad idea.

To raise money from the markets whilst the share price is where it is. Don't forget the cash struggles, litigation and actually what is going on around them, and of course Putin to try and negotiate with. It really could do with funds to tide it over just in case of any eventuality so tread carefully.

Https://x.com/MailOnline/status/1864302870419411025?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet

Taverham it's all subject to due diligence. There will be a few months wait and the deal could be reneged at any point. It's got a fair way to go to the finishing line.

The announcement of any firm offer under Rule 2.7 of the Code is subject to the satisfaction or waiver of several customary pre-conditions, including the completion of confirmatory due diligence.

Unfortunately antivaccers in the Oval Office will not be good for developmental pharma shares. Wasn't it Trump who thought you could treat Covid by injecting disinfectant. This is the mindset you are up against.

Unfortunately when the share is trending down on wider macro factors it's better to sell out and park up. Then buy back cheaper. It will probably venture into the teens tomorrow. This is where the previous Director sales get used against them. Should have kept them in tight hands.

"Land Sea and Air" soz

WSG could never leave Aim as it relies on it for relentless placings and that dreaded death spiral finance alternative of the Convertible Loan notes.

The last strategic review came up with Land, Sea and Water with a deck chair reshuffling of websites and little meaningful else for investors.

Thanks for the project based finance reminder grabs. It was never happening.

Next MOU or Contract always needs more money and more of the above as thats what the business model demands.

Sadly I won't be investing and I'm out, as they say on Dragons Den.

So no Bank or debt funding arrived, quelled surprise, and it was back to a convertible loan and a subscription or private placing with warrants.

Always hype, then it serially disappoints.

The best strategic review the company could do is to bring in external management consultants and perhaps have a clear out.

Sorry for anyone that got caught out with the post DRC hype of inflated share prices.